High HMGN1 levels drive leukemia in Down syndrome
Nature Genetics
April 21, 2014
A genetic cause of the link between Down syndrome and B cell acute lymphoblastic leukemia (B-ALL) in both mice and human cells is reported in a paper published online this week in Nature Genetics. The study identifies a promising drug target to treat B-ALL in Down syndrome.
People with Down syndrome are at a 20-fold risk of developing a type of B-ALL, an aggressive cancer of the white blood cells. David Weinstock and colleagues found that having three copies of a small region of 31 genes on chromosome 21 was sufficient to drive the cancer. Using a combination of experiments in mice and human cells, they found that increased levels of a specific protein, HMGN1, turns on the group of genes needed for the cancer to spread. The increase in HMGN1 levels was specific to Down syndrome B-ALL, but not other types of ALL.
The authors speculate that drugs that inhibit HMGN1 could prove useful for treating B-ALL in Down syndrome patients.
doi: 10.1038/ng.2949
Research highlights
-
Dec 4
Archaeology: Palaeolithic sea voyage to Japanese islands beyond the horizonScientific Reports
-
Dec 3
Ageing: Cellular rejuvenation restores vision in miceNature
-
Dec 1
Neurodegenerative disease: Two blood molecules may predict Alzheimer’s disease developmentNature Aging
-
Nov 27
Archaeology: Neanderthal thumbs better adapted to holding tools with handlesScientific Reports
-
Nov 26
Evolution: Ancient bird sticks its big beak into the evolutionary recordNature
-
Nov 26
Metabolism: Link between SARS-CoV-2 infection and cholesterol hints at COVID-19 treatment possibilitiesNature Metabolism
